Adiposity Measures in Metabolic Syndrome among Hausas in Kano, Northern Nigeria
Gako-hitzak:
Adiposity measures, metabolic syndrome, metabolic syndrome biomarkers, Hausas, Northern NigeriaLaburpena
Summary: Ethnic variations exist in the relationship of adiposity indices with metabolic syndrome (MetS). There are however, limited studies on the usefulness of body adiposity index (BAI) and visceral adiposity index (VAI) among Hausas of Kano, Northern Nigeria. The aim of the study was to determine the relationship of measures of adiposity to the components of MetS in Hausas of Kano. The study included 465 (266 males and 199 females) subjects, with mean age of 34.4 years and 32.0 years for males and females respectively. Anthropometric measures were obtained using standard protocols. Visceral adiposity was estimated using sex specific VAI. Fasting blood sample was obtained for serum analyses of lipid profiles, glucose, protein and uric acid. Pearson’s correlation was used to test the association between adiposity measures with MetS indices while Student’s t test was used for group comparison. The results of the study showed that the adiposity indices significantly correlate with metabolic syndrome indices. Visceral adiposity index was superior to other adiposity measures and Waist to hip ratio was the strongest anthropometric correlate of MetS components. In conclusion, WHR is the strongest anthropometric correlate of MetS components. Body adiposity index, NC and HC are weaker adiposity tools. Visceral adiposity index is superior to all other adiposity tools.
Erreferentziak
Adiels M, Taskinen MR, Boren J. 2008. Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep 8: 60–64
Akuyam SA, Aghogho UB, Aliyu, IS Bakari, A.G (2009). Serum total cholesterol in hypertensive Northern Nigerians. Int J Med Med Sci 3: 73 – 78
Amato M, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M. 2010.Visceral Adiposity Index A reliable indicator ofvisceral fat function associated with cardiometabolic risk. Diabetes Care 33(4): 920-2.
Amato MC, Giordano C. 2014. Visceral adiposity index: an indicator of adipose tissue dysfunction. International Journal of Endocrinology, (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009335/http://www.hindawi.com//ije/2014/730827/): 730827.
Andersen, L. B. (2006). Physical activity and clustered cardiovascular risk in children: a cross-sectional study (The European Youth Heart Study). Lancet,368: 299–304
Bélanger C, Luu-The V, Dupont P, Tchernof A. 2002. Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity. Horm Metab Resource 34: 737–745
Bergman RN, Kim SP, Catalano KJ, Hsu IR, Chiu JD, Kabir M. 2006. Why visceral fat is bad: mechanisms of the metabolic syndrome. Obes 1:16S-19S, http://dx.doi.org/10.1038/oby. 2006.277.
Bergman RN, Stefanovski D, Buchanan TA. 2011. A better index of body adiposity. Obes. 19:1083-1089.
Billiet L, Doaty S, Katz JD, Velasquez MT. 2014. Review of hyperuricemia as new marker for metabolic syndrome. ISRN Rheumatol 85:29-54
Browning LM, Hsieh SD, Ashwell, M. 2010. A systematic review of waist-to-height ratio as ascreening tool for the prediction of cardiovascular disease and diabetes: 0.5 could bea suitable global boundary value. Nutr Res Rev 23: 247–269.
Butte NF, Puyau MR, Adolph AL, Vohra FA, Zakeri I. 2007. Physical activity in non overweight and overweight Hispanic children and adolescents. Med Sci Sports Exerc 39: 1257–1266.
Caraway WT. 1955. Determination of concentration of serum uric acid. Am J Clin Pathol 25: 840
Charles-Davies M.A.& Arinola, Arinola G, Ganiyu and Fasanmade et al. 2012. Indices of metabolic syndrome in 534 apparently healthy in a local market in Ibadan, Nigeria. J. US-China med. Sci. 9. 91 - 100
Després JP, Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, et al. 2000. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipaseactivity in men and women: the Health, Risk Factors, Exercise Training, Genetics (HERITAGE) family study. Arterioscler Thromb Vasc Biol 20: 1932–1938
Deurenberg P, Yap M, van Staveren WA. 1998. Body mass index and percent body fat: ameta analysis among different ethnic groups. Int J Obes Relat Metab Disord 22: 1164– 1171
Deurenberg, P., Yap, M. and van Staveren, W.A (1998). Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes Relat Metab Disord 22: 1164– 1171
Dusserre, E. and Moulin, P, and Vidal, H.(2000). Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophy Acta 1500:88-96.
Eckel RH, Alberti, KG, Grundy SM. Zimmet PZ. 2010. The metabolic syndrome. Lancet, 375:181-183.
Engeli S, Feldpausch M, Gorzelniak K, Hartwig G, Heintze U, Janke, J, 2003. Association between adiponectin and mediators of inflammation in obese women. Diab 52: 942–947.
Ford ES, Mokdad AH, Giles WH. 2003. Trends in waist circumference among U.S. adults. Obesity Research 11:1223–1231.
Friedewald WT, Levy RI. Fredrickson DS. 1972. Estimation of concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18:499-50
Goh LGH, Dhaliwal SS, Welborn TA, Lee AH, Della PR. 2014.Ethnicity and the association between anthropometric indices of obesity and cardiovascular risk in women: a cross-sectional study. British Medical Journal, 4:e004702. doi:10.1136/bmjopen-004702
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA. 2005. Diagnosis and management of the metabolicsyndrome: an American Heart Association/NationalHeart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735-52.
Haffner SM, Ferrannini E, Hazuda HP, Stern MP. 2005. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension 20:38-45
Haffner SM, Ferrannini, E., Hazuda, H.P. and Stern, M.P. (2005) Clustering of cardiovascularrisk factors in confirmed prehypertensive individuals. Hypertension, 20:38-45
Hotta K, Funahashi T, Bodkin NL. 2001. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diab 50:1126-1133.
Johnson RJ, Gaucher EA, Sautin YY, Henderson GN, Angerhofer AJ, Benner SA. 2008. The planetary biology of ascorbate and uric acid and their relationship with the epidemic of obesity and cardiovascular disease. Med Hypotheses 71:22-31.
Kadiri S, Salako BL. 1997. Cardiovascular risk factors in middle aged Nigerians. East Afr Med J 74(5):303–6.
Katzmarzyk PT, Bray GA, Greenway FL, Johnson WD, Newton RL, Ravussin E, et al. 2011. Ethnic-specific BMI and waist circumference thresholds. Obes 19: 1272–1278
Knowles KM, Paiva LL, Sanchez SE, Revilla L, Lopez T, Yasuda MB. 2011. Waist Circumference, Body Mass Index, andOther Measures of Adiposity in Predicting Cardiovascular DiseaseRisk Factors among Peruvian Adults. Int J Hypert 11:1-10.
Heloisa, G., Fernanda, S.A., Antunes, M.T et al. (2015). Applicability of visceral adiposity index in prediction of components of metabolic syndrome in elderly. Nutrition Hospital, 32(4):1609-1615
Korenblat KM, Fabbrini E, Mohammed BS, Klein S. 2008. Liver, muscle, and adipose tissueinsulin action is directly related to intrahepatic triglyceride content in obese subjects.Gastroenterol 134: 1369–1375
Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ, Storlien LH. 1991. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diab 40:1397– 403.
Lara-Castro C, Weinsier RL, Hunter GR, Desmond R. 2002. Visceral adipose tissue inwomen: longitudinal study of the effects of fat gain, time, and race. Obesity Resource, 10: 868–874
Lean ME, Han TS, Morrison CE. 1995. Waist circumference as a measure for indicating need for weight management. British Med J 311(6998):158e61
Lear SA, James PT, Ko GT, Kumanyika, S. 2010. Appropriateness of waist circumference andwaist-to-hip ratio cutoffs for different ethnic groups. Eur J Clin Nutr 64: 42–61.
MacKay MF, Haffner SM, Wagenknecht LE, D’Agostino RB, Jr Hanley AJ. 2009. Prediction of type 2 diabetes using alternate anthropometric measures in a multi-ethnic cohort: the insulin resistance atherosclerosis study. Diab Care. 32(5):956-8
Mahmoud US, Kolawole WW, Bashir OY, Maruf G, Omolara VJ, Akeem G. 2010. Modifiable cardiovascular risk factors among apparently healthy adult Nigerian population - a cross sectional study. BMC Res Notes 3:11.
Mathieu P, Poirier P, Pibarot P, Lemieux I, Després JP. 2009. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypert 53: 577–584.
Matsuzawa Y. 2005. Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler 6: 7–14.
Matsuzawa Y. 2008. The role of fat topology in the risk of disease. Int J Obes7:83–92
MbanyaVN, Kengne AP, Mbanya JC, Akhtar H. 2015. Body mass index, waist circumference, hip circumference, waist–hip-ratio and waist–height-ratio: Which is the better discriminator of prevalent screen-detected diabetes in a Cameroonian population? Diabetes Res Clin Pract 62: 91-98
Melmer A, Lamina C, Tschoner A, Ress C, Kaser S, Laimer M. 2013 Body Adiposity Index and other indexes of body composition in SAPHIR study: Association with cardiovascular risk factors. Obes 21: 775-771
Moller DM, Kaufman KD. 2005. Metabolic syndrome: a clinical and molecular perspective. Ann Rev Med 56: 45–62.
Okamkpa CJ, Nwankwo M, Danborno, B. 2016. Predicting high blood pressure among adults in Southeastern Nigeria using anthropometric variables. J Exp Clin Anat 15: 111-7
Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, et al. (2002). Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106: 2767–2770
Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y. 2001. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103: 1057–1063.
Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, OvervadK, et al. (2008). General and abdominal adiposity and risk of death in Europe. N Engl J Med 359(20):2105-21.
Pischon T, Hotamisligil GS, Rimm EB. 2003. Adiponectin Stability in plasma over 36 hours and within person variation over 1 year. Clin Chem 49:650-652
Prisant LM, Alpert BS, Robbins CB, Berson AS, Hayes M, Cohen ML, et al. 1995. American National Standard for non automated sphygmomanometers: summary report. Am J Hypert8: 210 –213
Razak F, Anand SS, Shannon H, Vuksan V, Davis B, Jacobs R, et al. 2007. Defining obesity cut points in a multiethnic population. Circulation 115: 2111– 2118.
Ross R, Janiszewski PM. 2006. Is weight loss the optimal target for obesity-related cardiovasculardisease risk reduction? Canadian J Cardiol 24: 25–31.
Shao J, Yu L, Shen X, Li D, Wang K. 2010. Waist-to-height ratio, an optimal predictor for obesity and metabolic syndrome in Chinese adults. J Nutr Health Aging14: 782–785.
Stefan N, Stumvoll M, Vozarova B, Weyer C, Funahashi T, Matsuzawa Y, et al. 2003. Plasma adiponectin and endogenous glucose production in humans. Diabetes Care 26: 3315 - 3319.
Stefan N, Vozarova B, Funahashi T. 2002. Concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 51:1884- 1888
Trinder P. 1969. Determination of serum glucose. Ann Clin Biochem 6:24-27
Tulloch-Reid MK, Williams DE, Looker HC, Hanson RL, Knowler WC. 2003. Do measures of body fat distribution provide information on the risk of type 2 diabetes in addition to measures of general obesity? Comparison of anthropometric predictors of type 2 diabetes in Pima Indians. Diabetes Care 26: 2556–2561
Weyer C, Funahashi T, Tanaka S. 2001. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metabol 86:1930-1935.
Wybenga DR, Pileggi VJ, Dirstine, PH, Di Giorgio J. 1970. Methods of measuring serum lipids. Clin Chem. 16:980
Yamauchi, T., Kamon, J., Minokoshi, Y., Ito. Y., Waki, H., Uchida, S., Yamashita, S., Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, et al. 2002. Adiponectin stimulates glucose utilization and fattyacid oxidation by activating AMP-activated protein kinase. Nature Med 8: 1288–1295.
Deskargak
Argitaratua
Zenbakia
Atala
Lizentzia
Lan hau Creative Commons Aitortu-EzKomertziala-LanEratorririkGabe 4.0 Nazioarteko Lizentziapean dago argitaratuta.
